Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000414135 | SCV000491596 | pathogenic | not provided | 2016-10-19 | criteria provided, single submitter | clinical testing | The C136X pathogenic variant in the FLAD1 gene has not been reported previously as a pathogenic variant nor as a benign variant, to our knowledge. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The C136X variant was not observed in approximately 6500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. We interpret C136X as a pathogenic variant. |
Labcorp Genetics |
RCV000414135 | SCV002957866 | pathogenic | not provided | 2025-01-12 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Cys136*) in the FLAD1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FLAD1 are known to be pathogenic (PMID: 27259049). This variant is present in population databases (no rsID available, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with FLAD1-related conditions. ClinVar contains an entry for this variant (Variation ID: 373037). For these reasons, this variant has been classified as Pathogenic. |
Genomics England Pilot Project, |
RCV001542550 | SCV001759989 | pathogenic | Myopathy with abnormal lipid metabolism | no assertion criteria provided | clinical testing |